INTERNATIONAL CONFERENCE
IMMUNE AND CELLULAR THERAPIES:
Focus on Immune Based Therapeutic Concepts
Mandelieu, France
September 20-22, 2019
Chairs: Chiara Bonini, Carl June, Max Topp

Friday, September 20, 2019

08:30–08:45 Welcome

SESSION I – UPDATES IN CAR T CELL THERAPY FOR B-CELL TUMOURS
Chair: Michael Jensen

08:45-09:00	ALL and DLBCL	Cameron Turtle (Seattle)
09:00-09:05	*Discussion*	
09:05-09:20	Prophylactic vs pre-emptive tocilizumab	Shannon Maude (Philadelphia)
09:20-09:25	*Discussion*	
09:25-09:40	Treatment of lymphoma	Stephen Schuster (Philadelphia)
09:40-09:45	*Discussion*	
09:45-10:00	Blocking co-stimulation as anti-myeloma immunotherapy	Kelvin Lee (Buffalo)
10:00-10:05	*Discussion*	
10:05-10:12	*T cell dynamics in chronic lymphocytic leukemia under different treatment modalities: implications for combination immunotherapies*	*Anna Vardi (Stockholm)*
10:12-10:15	*Discussion*	
10:15-10:35	*Panel discussion*	

10:35-11:05 Coffee Break

SESSION II – CAR T CELL THERAPIES FOR ACUTE MYELOID LEUKAEMIA AND MULTIPLE MYELOMA
Chair: Cameron Turtle

11:05-11:20	CD44v6 CAR T cells for AML and MM	Fabio Ciceri (Milan)
11:20-11:25	*Discussion*	
11:25-11:40	BCMA CAR T for Myeloma	Kristen Hege (San Francisco)
11:40-11:45	*Discussion*	
11:45-12:00	CD19 and BCMA CAR T for Myeloma	Alfred Garfall (Philadelphia)
12:00-12:05	*Discussion*	

12:05-12:12	*CD38-specific nanobody-based chimeric antigen receptors (CARs) targeting CD38 expressing multiple myeloma cells*	*Julia Hambach (Hamburg)*
12:12-12:15	*Discussion*	
12:15-12:35	*Panel discussion*	

12:35-14:15 ***Lunch***

13:05-14:05 **SATELLITE SYMPOSIUM**
CAR T cell therapy in haematological malignancies
Leveraging the immune system to optimize clinical outcomes
Chair: Stephen Schuster
Speakers: Stephen Schuster (Philadelphia), Catherine Thieblemont (Paris)

This educational symposium is organized and funded by Celgene.

SESSION III – MANAGEMENT OF RESISTANCE AND TOXICITY TO CAR T CELLS
Chair: Chiara Bonini

14:15-14:30	Modeling cytokine release syndrome: challenges of defining the undefinable	David Barrett (Philadelphia)
14:30-14:35	*Discussion*	
14:35-14:50	Overcoming antigen escape in the setting of CAR T Cell immunotherapy	Michael Jensen (Seattle)
14:50-14:55	*Discussion*	
14:55-15:10	Understanding resistance to develop better CART immunotherapies	Marco Ruella (Philadelphia)
15:10-15:15	*Discussion*	
15:15-15:30	Next Generation CAR T-cell for Therapy	Renier Brentjens (New-York)
15:30-15:35	*Discussion*	
15:35-15:42	*A single cell multi-omics approach reveals distinct cellular and molecular signatures associated to cytokine release and persistence of CAR CD19 T cells*	*Fabio Luciani (Sydney)*
15:42-15:45	*Discussion*	
15:45-16:05	*Panel discussion*	

16:05-16:35 ***Coffee break***

SESSION IV – BiTEs AND OTHER ENGINEERED ANTIBODY THERAPIES
Chair: Max Topp

16:35-16:55	MRD positive Acute Lymphoblastic Leukaemia	Nicola Gökbuget (Frankfurt)
16:55-17:00	*Discussion*	
17:00-17:20	Relapsed/ Refractory Acute Lymphoblastic Leukaemia	Max Topp (Würzburg)
17:20-17:25	*Discussion*	

17:25-17:45	Bispecific antibodies for acute myeloid leukaemia. Early results and challenges	John Godwin (Portland)
17:45-17:50	*Discussion*	
17:50-18:10	Non-Hodgkin Lymphoma	Rajat Bannerji (New Brunswick,NJ)
18:10-18:15	*Discussion*	
18:15-18:22	*Tumor intrinsic and extrinsic mechanisms of response and resistance to blinatumomab*	*Yaqi Zhao (Memphis)*
18:22-18:25	*Discussion*	
18:25-18:45	*Panel discussion*	
18:45-19:30	***Tutored poster walks and welcome get together***	

Saturday, September 21, 2019

09:00-10:00 3 Meet the Expert sessions (non-clinical)

- Manufacturing of CAR T cells for clinical trials with a special view on manufacturing challenge	Ulrike Köhl (Leipzig)
- Targeting non classical HLA molecules for cancer immunotherapy	Giulia Casorati (Milan)
- Manufacturing of virus-specific T cells with a focus on specific patient and donor issues	Patrizia Comoli (Pavia)

09:00-10:00 **SATELLITE SYMPOSIUM**
Understanding CAR-T: from trial design to patient management
Chair: Gilles Salles
Speakers: Roberta Di Blasi (Paris), Gilles Salles (Lyon), Fabio Ciceri (Milan)

This educational symposium is organized and funded by Novartis.

10:00-10:30 Coffee break

SESSION V – CELLULAR THERAPIES FOR INFECTIONS
Chair: Fabio Ciceri

10:30-10:45	Adoptive cellular therapy with multi virus-specific T-cells	Tobias Feuchtinger (Munich)
10:45-10:50	*Discussion*	
10:50-11:05	Treatment with banked 3rd party donor-derived, virus-specific T-cells: the advantages of pre-defined HLA restriction and epitope specificity	Ekaterina Doubrovina (New-York)
11:05-11:10	*Discussion*	
11:10-11:25	Cellular therapy for CMV: overcoming obstacles to clinical application	Karl Peggs (London)
11:25-11:30	*Discussion*	
11:30-11:45	Polyomavirus JC-specific T cells for the treatment of progressive multifocal leukoencephalopathy	Patrizia Comoli (Pavia)
11:45-11:50	*Discussion*	

11:50-12:05	IL-1R8, a checkpoint molecule in NK cell-mediated anti-tumoral and anti-viral activity	Cecilia Garlanda (Milan)
12:05-12:10	*Discussion*	
12:10-12:30	*Panel discussion*	

12:30-13:30 Lunch

SESSION VI – NON-T CELL THERAPIES (MSC, GAMMA-DELTA T-CELLS, ETC.)
Chair: Michael Jensen

13:30-13:45	Alpha/Beta T-cell depleted transplants	Franco Locatelli (Rome)
13:45-13:50	*Discussion*	
13:50-14:05	Immunosuppressive activity of MSC: resolving the mechanism of action	Francesco Dazzi (London)
14:05-14:10	*Discussion*	
14:10-14:25	Adoptive cell therapy with CD1 restricted T cells	Giulia Casorati (Milan)
14:25-14:30	*Discussion*	
14:30-14:45	From CAR T cells to CAR NK cells for improvement of cancer retargeting	Ulrike Köhl (Leipzig)
14:45-14:50	*Discussion*	
14:50-15:05	Gamma-Delta- TCR engineered T cells	Jürgen Kuball (Utrecht)
15:05-15:10	*Discussion*	
15:10-15:17	*Allogeneic CD19 chimeric antigen receptor (CAR) cytokine induced killer (CIK) CELLS with sleeping beauty (SB) transposon for adoptive immunotherapy*	*Chiara F. Magnani (Milan)*
15:17-15:20	*Discussion*	
15:20-15:40	*Panel discussion*	

15:40-16:10 Coffee Break

SESSION VII – IMMUNE THERAPY STRATEGIES FOR SOLID TUMOURS
Chair: Patricia Comoli

16:10-16:25	CAR T cells for solid tumours	Gianpietro Dotti (Chapel Hill)
16:25-16:30	*Discussion*	
16:30-16:45	Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumours	Yong Gu Lee (Philadelphia)
16:45-16:50	*Discussion*	
16:50-17:05	Advancing CAR T cell therapy for treatment of brain tumours	Darya Alizadeh (Duarte)
17:05-17:10	*Discussion*	
17:10-17:25	TRUCKS against solid cancer: CAR T cells delivering IL-18	Hinrich Abken (Cologne)
17:25-17:30	*Discussion*	

17:30-17:45	Clinical trials with TCR engineered T cells	Aude Chapuis (Seattle)
17:45-17:50	*Discussion*	
17:50-18:05	Development of a CAR-T cell program in Qatar	Cristina Maccalli (Doha)
18:05-18-10	*Discussion*	
18:10-18:17	*Combined immunotherapy treatment to prevent pediatric sarcoma metastasis*	*Maria Vela (Madrid)*
18:17-18:20	*Discussion*	
18:20-18:40	*Panel discussion*	

Sunday, September 22, 2019

07:45-8:45 3 Simultaneous Meet the Expert Sessions (Clinical)

- Patient selection of DLBCL patients for CAR-T therapy	Max Topp (Würzburg)
- AML patients	Fabio Ciceri (Milan)
- Gamma-Delta- TCR engineered T cells	Jürgen Kuball (Utrecht)

SESSION VIII – CELLULAR THERAPIES FOR GVHD (MSC, SUICIDE GENES, ETC.)
Chair: Jurgen Kuball

09:00-09:15	From suicide genes to TCR gene editing: adoptive cell therapies in haematological cancers	Chiara Bonini (Milan)
09:15-09:20	*Discussion*	
09:20-09:35	Placenta derived decidua stromal cells for severe acute GVHD and toxicity following allogeneic HSCT	Olle Ringden (Huddinge)
09:35-09:40	*Discussion*	
09:40-09:55	Treg cell therapy in allogeneic stem cell transplantation	Matthias Edinger (Regensburg)
09:55-10:00	*Discussion*	
10:00-10:15	Application of CAR technology to regulatory T cells	Megan Levings (Vancouver)
10:15-10:20	*Discussion*	
10:20-10:27	*Suppression of GvHD and augmentation of Gvl by allogeneic human DNT cells and underlying mechanisms*	*Li Zhang (Toronto)*
10:27-10:30	*Discussion*	
10:30-10:50	*Panel discussion*	
10:50-11:20	***Coffee Break***	

SESSION IX – LATE BREAKING SESSION
Chair: Megan Levings

11:20-11:35	Strategies to Improve CAR T Efficacy in Relapsed/Refractory NHL	Wei-Dong Han (Beijing)
11:35-11:40	*Discussion*	
11:40-11:55	Is Tafasitamab an alternative to CAR-T?	Johannes Düll (Würzburg)
11:55-12:00	*Discussion*	

12:00-12:15	The tyrosine kinase inhibitor dasatinib acts as a pharmacologic ON/OFF switch for CAR-T-cells to prevent cytokine release syndrome	Katrin Mestermann (Würzburg)
12:15-12:20	*Discussion*	
12:20-12:35	Monocyte/macrophage-based interferon delivery into the tumor microenvironment by transplantation of gene-engineered autologous hematopoietic stem and progenitor cells	Bernhard Gentner (Milan)
12:35-12:40	*Discussion*	
12:40-12:47	*Enabling assembly lines for cellular therapies via acoustofluidic intracellular delivery of biomolecular cargo*	*Steven Jonas (Los Angeles)*
12:47-12:50	*Discussion*	
12:50-13:10	*Panel discussion*	
13:10-13:20	***Closing Remarks***	

MEETING CLOSURE